| Title: |
International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations? |
| Authors: |
Calice-Silva, Viviane1,2 (AUTHOR), Muenz, Daniel3 (AUTHOR), Wong, Michelle M. Y.4 (AUTHOR), McCullough, Keith3 (AUTHOR), Charytan, David5 (AUTHOR), Reichel, Helmut6 (AUTHOR), Robinson, Bruce3 (AUTHOR), Stengel, Benedicte7,8 (AUTHOR), Massy, Ziad A.7,8,9 (AUTHOR), Pecoits-Filho, Roberto3 (AUTHOR) Roberto.Pecoits@ArborResearch.org, on behalf of CKDopps Investigators (AUTHOR), Lopes, Antonio (AUTHOR), Combe, Christian (AUTHOR), Jacquelinet, Christian (AUTHOR), Massy, Ziad (AUTHOR), Duttlinger, Johannes (AUTHOR), Fliser, Danilo (AUTHOR), Lonnemann, Gerhard (AUTHOR), Wada, Takashi (AUTHOR), Yamagata, Kunihiro (AUTHOR) |
| Source: |
Lipids in Health & Disease. 5/25/2023, Vol. 22 Issue 1, p1-10. 10p. |
| Subject Terms: |
*CHRONIC kidney failure, *CHRONICALLY ill, *DYSLIPIDEMIA, *OLDER patients, *KIDNEY disease diagnosis, *BLOOD lipoproteins |
| Geographic Terms: |
FRANCE, BRAZIL |
| Abstract: |
Background: In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods: We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results: LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion: There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Lipids in Health & Disease is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
